-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
In recent years, the efficiency of drug approval in China has been greatly improved
.
From the perspective of approval time, the approval time for clinical trials of innovative drugs has dropped from 15 years and more than 20 months to 3 months, a decrease of 87%
.
In terms of the number of new drugs approved, only 7 new drugs were approved in 2016, and the number of new drugs approved in 2020 will rise to 45
.
With the continuous reform of the system and mechanism in the fields of drug research and development, approval, production, circulation, and use, China's pharmaceutical industry has achieved mid-to-high-speed development and transition to mid-to-high-end industries
.
At the same time, some pharmaceutical companies have continuously expanded their investment in pharmaceutical research and development, which has further promoted the development of innovative drugs in China
.
Statistics show that 401 companies have more than 167,000 R&D personnel, and China's pharmaceutical industry is ushering in the era of "innovative drugs"
.
Among them, Hengrui Medicine has more than 4700 R&D personnel
.
It is understood that in recent years, Hengrui Pharmaceuticals has continuously introduced high-level talents at home and abroad to give full play to the role of high-end talents
.
Statistics show that in 2020, Hengrui Pharmaceuticals will bring in more than 200 doctoral students, more than 100 talents with overseas study and work experience, and more than 400 core technical talents
.
As of the end of 2020, Hengrui Medicine has 4,721 R&D personnel, accounting for 16.
33% of the company's total number
.
In addition, data shows that Hengrui Pharmaceuticals has also continuously increased its R&D investment in recent years.
In 2020, Hengrui Pharmaceuticals invested nearly 5 billion yuan in R&D funds, an increase of 28% year-on-year, and R&D investment accounted for 17.
99% of sales revenue, which is the company’s innovative drug development.
Provides strong support
.
Let's look at Shanghai Pharmaceuticals.
In recent years, Shanghai Pharmaceuticals has continuously increased its investment in research and development, and its R&D team has also been continuously expanded
.
From 2016 to 2020, in the five years, Shanghai's pharmaceutical R&D investment has increased by nearly three times, with a compound annual growth rate of approximately 31%
.
The data shows that from 2016 to 2020, the amount of Shanghai pharmaceutical R&D investment reached 671 million yuan, 836 million yuan, 1.
389 billion yuan, 1.
509 billion yuan, and 1.
972 billion yuan respectively.
.
During this period, the number of R&D personnel in Shanghai Pharmaceuticals has also continued to grow.
Data shows that from 2016 to 2020, the number of R&D personnel in Shanghai Pharmaceuticals will be 853, 866, 1,020, 1,200, and 1,347 respectively
.
In addition, data shows that Junshi Bio's R&D investment has also risen sharply from 2018 to 2020.
During this period, R&D investment increased by 95.
49% year-on-year to 538 million yuan, 75.
80% to 946 million yuan, and 87.
93% to 1.
778 billion yuan
.
It is reported that the number of Junshi Biological R&D personnel has reached 667, accounting for 27.
19% of the total number
.
It is understood that these pharmaceutical companies continue to achieve new breakthroughs in the field of innovative drugs with the increase in R&D investment and the growth of R&D teams
.
For example, Hengrui Medicine has basically formed an innovative drug application for clinical trials every year, and a benign development trend of innovative drugs being marketed every 1-2 years
.
For example, as of the end of 2020, Hengrui Medicine has 7 innovative drugs approved for marketing, and 12 innovative drugs are already in the phase 3 clinical stage and the marketing application stage
.
In recent years, Shanghai Pharmaceuticals has also significantly accelerated the progress of its innovative drug pipeline.
As of the end of 2020, the company has 25 products in the pre-clinical and follow-up research phases of innovative drug pipelines, 15 products have entered clinical trials or have been on the market, and 13 projects have been obtained.
Progress in stages
.
Similarly, strong R&D support also empowers the development of Junshi Bio-innovative drugs
.
It is reported that one of its core products, tereprizumab (JS001), is the first domestic anti-PD-1 monoclonal antibody approved by NMPA to be marketed.
At present, a rich clinical and R&D pipeline has been established, covering malignant tumors and self Immune system diseases, chronic metabolic diseases, nervous system diseases and infectious diseases are five major disease areas
.
.
From the perspective of approval time, the approval time for clinical trials of innovative drugs has dropped from 15 years and more than 20 months to 3 months, a decrease of 87%
.
In terms of the number of new drugs approved, only 7 new drugs were approved in 2016, and the number of new drugs approved in 2020 will rise to 45
.
With the continuous reform of the system and mechanism in the fields of drug research and development, approval, production, circulation, and use, China's pharmaceutical industry has achieved mid-to-high-speed development and transition to mid-to-high-end industries
.
At the same time, some pharmaceutical companies have continuously expanded their investment in pharmaceutical research and development, which has further promoted the development of innovative drugs in China
.
Statistics show that 401 companies have more than 167,000 R&D personnel, and China's pharmaceutical industry is ushering in the era of "innovative drugs"
.
Among them, Hengrui Medicine has more than 4700 R&D personnel
.
It is understood that in recent years, Hengrui Pharmaceuticals has continuously introduced high-level talents at home and abroad to give full play to the role of high-end talents
.
Statistics show that in 2020, Hengrui Pharmaceuticals will bring in more than 200 doctoral students, more than 100 talents with overseas study and work experience, and more than 400 core technical talents
.
As of the end of 2020, Hengrui Medicine has 4,721 R&D personnel, accounting for 16.
33% of the company's total number
.
In addition, data shows that Hengrui Pharmaceuticals has also continuously increased its R&D investment in recent years.
In 2020, Hengrui Pharmaceuticals invested nearly 5 billion yuan in R&D funds, an increase of 28% year-on-year, and R&D investment accounted for 17.
99% of sales revenue, which is the company’s innovative drug development.
Provides strong support
.
Let's look at Shanghai Pharmaceuticals.
In recent years, Shanghai Pharmaceuticals has continuously increased its investment in research and development, and its R&D team has also been continuously expanded
.
From 2016 to 2020, in the five years, Shanghai's pharmaceutical R&D investment has increased by nearly three times, with a compound annual growth rate of approximately 31%
.
The data shows that from 2016 to 2020, the amount of Shanghai pharmaceutical R&D investment reached 671 million yuan, 836 million yuan, 1.
389 billion yuan, 1.
509 billion yuan, and 1.
972 billion yuan respectively.
.
During this period, the number of R&D personnel in Shanghai Pharmaceuticals has also continued to grow.
Data shows that from 2016 to 2020, the number of R&D personnel in Shanghai Pharmaceuticals will be 853, 866, 1,020, 1,200, and 1,347 respectively
.
In addition, data shows that Junshi Bio's R&D investment has also risen sharply from 2018 to 2020.
During this period, R&D investment increased by 95.
49% year-on-year to 538 million yuan, 75.
80% to 946 million yuan, and 87.
93% to 1.
778 billion yuan
.
It is reported that the number of Junshi Biological R&D personnel has reached 667, accounting for 27.
19% of the total number
.
It is understood that these pharmaceutical companies continue to achieve new breakthroughs in the field of innovative drugs with the increase in R&D investment and the growth of R&D teams
.
For example, Hengrui Medicine has basically formed an innovative drug application for clinical trials every year, and a benign development trend of innovative drugs being marketed every 1-2 years
.
For example, as of the end of 2020, Hengrui Medicine has 7 innovative drugs approved for marketing, and 12 innovative drugs are already in the phase 3 clinical stage and the marketing application stage
.
In recent years, Shanghai Pharmaceuticals has also significantly accelerated the progress of its innovative drug pipeline.
As of the end of 2020, the company has 25 products in the pre-clinical and follow-up research phases of innovative drug pipelines, 15 products have entered clinical trials or have been on the market, and 13 projects have been obtained.
Progress in stages
.
Similarly, strong R&D support also empowers the development of Junshi Bio-innovative drugs
.
It is reported that one of its core products, tereprizumab (JS001), is the first domestic anti-PD-1 monoclonal antibody approved by NMPA to be marketed.
At present, a rich clinical and R&D pipeline has been established, covering malignant tumors and self Immune system diseases, chronic metabolic diseases, nervous system diseases and infectious diseases are five major disease areas
.
